Lynparza May Significantly Improve Outcomes for Ovarian Cancer Patients, Trial Shows

Lynparza May Significantly Improve Outcomes for Ovarian Cancer Patients, Trial Shows
Certain ovarian cancer patients with BRCA mutations may benefit from maintenance treatment with the PARP inhibitor Lynparza (olaparib). The therapy significantly increases progression-free survival, according to the results of a Phase 3 trial recently released by AstraZeneca. Lynparza was the first PARP inhibitor to be approved for patients with germline BRCA-mutated advanced ovarian cancer. It works

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *